Pharmaceutical Intermediate Sunifiram Powder Top Quality

Pharmaceutical Intermediate Sunifiram Powder Top Quality

Información básica.

nombre del producto: Sunifiram
As: DM-235
CASO: 314728-85-3
MF: C14H18N2O2
MW: 246.30492
Apariencia: Off-white to white crystalline powder

Abstracto

Sunifiram is one of the newest nootropics on the market to smart drugs family. It is considered to be in the ampakine family of supplements. It increases one’s attention span, Toma de decisiones, and learning abilities. Although it is believed to work much like Piracetam, it is highly potent in comparison. The structure is similar, but some have reported Sunifiram being 1000 times more potent. In terms of its potency, it’s comparable to Noopept.

It is being researched as a memory enhancer, potentially treating Alzheimer’s patients. It provides a wide variety of benefits including; increased attention span, improved focus, and increased learning potential. It has become very popular since its release, as the benefits are high and the side-effects are low.

Sunifiram Applications:

This compound is known as an AMPAkine due to exerting most of its actions via the AMPA receptor (one of the three main subsets of glutamate receptors, alongside NDMA and kainate). This enhancement of AMPA function seems to also rely on enhancing signalling via the Glycine binding site of NMDA receptors, although one minimal signalling goes through the NMDA receptor then the benefits on AMPA receptors seem dose-dependent.

Sunifiram (DM-235) es un fármaco ampaquina derivado de la piperazina que actúa como un modulador alostérico positivo de los receptores AMPA, and has nootropic effects in animal studies with significantly higher potency than piracetam. A number of related compounds are known, the best known being unifiram (DM-232).

This enhancement by sunifiram is associated with an increase inphosphorylation of AMPAR through activation of protein kinase II(CaMKII) and an increase in phosphorylation of NMDAR through activation of protein kinase C α (PKCα). Más específicamente, sunifiram stimulates the glycine-binding site of NMDAR with concomitant PKCαactivation through Src kinase. Enhancement of PKCα activity triggers to potentiate hippocampal LTP through CaMKII activation.Sunifiram improves cognitive deficits via CaM kinase II andprotein kinase C activation.